UPDATE: Click here to order samples for your practice.

WITH BAUSCH + LOMB, WE’VE GOT YOUR PATIENTS COVERED

Your eligible patients may pay no more than†:

Commercially Insured

$35
CO-PAY

Uninsured Patients

$75
CO-PAY

Medicare Part D

$60
CO-PAY

*MMIT data 2018.

†Terms and conditions apply. Please see www.bauschaccessprogram.com or www.prolensapartdcoupon.com for eligible criteria and terms and conditions.

COMMERCIAL PATIENT SAVINGS

Direct patients to www.bauschaccessprogram.com where they can activate a printed coupon or download a digital coupon, and review eligibility terms and conditions*.

Print coupons can also be activated by calling 1-866-693-4880.

  • Size: 3 mL
  • Eligible Commercially Insured May Pay*: $35
  • Eligible Uninsured May Pay*: $75
  • Eligible Fills: 6

Bausch + Lomb has aligned with Walgreens to stock product and help eligible patients redeem prescription savings on our products.

Contact your sales representative to provide in-office printed coupons.

If you have any questions regarding your eligibility or benefits, please call 1-866-693-4880.

*Terms and conditions apply. Please see www.bauschaccessprogram.com for eligibility criteria and terms and conditions

Bausch Access Program Website

SAVINGS FOR ELIGIBLE MEDICARE PART D PATIENTS†

The PROLENSA Part D Program offers savings for Medicare Part D patients. Most eligible patients pay no more than $60 co-pay on their PROLENSA® prescription†.

ACTIVATE:

Patients can activate the print coupon by calling 1-866-686-0091. To activate the online download coupon, patients must agree to the statements on www.prolensapartdcoupon.com.

REDEEM:

Patients can redeem the coupon card at a participating retail pharmacy with their prescription and insurance cards.

MAIL:

Patients sign and mail the prewritten letter to their health plan. Health care plan address can be found on their Medicare provider card.

Contact your sales representative to receive in-office printed coupons. If you have questions related to this program, please call 1-866-686-0091.

†Terms and conditions apply. Please see www.prolensapartdcoupon.com for eligibility criteria and terms and conditions.

PROLENSA Part D Program Website
Additional Resources

Indications and usage

PROLENSA® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Important Safety Information

  • PROLENSA® contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.
  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
  • PROLENSA® should not be instilled while wearing contact lenses. The preservative in PROLENSA®, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA®.
  • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Click here for full Prescribing Information for PROLENSA®.

© 2019 Bausch & Lomb Incorporated. All rights reserved. PRA.0018.USA.19

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION